Literature DB >> 11823087

Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival?

Robert J Scheubel1, Babett Bartling, Andreas Simm, Rolf Edgar Silber, Kostas Drogaris, Dorothea Darmer, Juergen Holtz.   

Abstract

OBJECTIVES: Activation of the caspase cascade through the mitochondrial and/or death receptor pathway was investigated in the failing human myocardium, in which the mode and extent of the cascade activation are unknown.
BACKGROUND: In terminal heart failure, a loss of cardiomyocytes by overload-induced apoptosis is an attractive mechanism, explaining the progressive character of the disease. However, its relevance is unclear, because the specificity of probes for apoptotic deoxyribonucleic acid damage is under debate.
METHODS: Left ventricular specimens from 36 explanted failing and 21 nonfailing donor hearts were used for messenger ribonucleic acid detection by semiquantitative reverse-transcription polymerase chain reaction. From these groups, immunoblot analysis was performed in samples from nine failing and six nonfailing donor hearts.
RESULTS: In terminally failing hearts, there was a significant accumulation of cytochrome c in the cytosol, which was associated with activation of caspase-9 and downregulation of its inhibitor, caspase-9S. Similarly, the death receptor-induced pathway revealed activation of caspase-8, combined with downregulation of its inhibitors, flice-like inhibitory protein-L (FLIP(L)) and FLIP(S). The unspecific caspase inhibitors, XIAP, hIAP-1 and hIAP-2, were also downregulated. However, the terminal effector caspase-3 was not activated, and its substrate gelsolin, acting in its uncleaved form as a feedback inhibitor of caspase-3, was not cleaved.
CONCLUSIONS: In the terminally failing human myocardium, the caspase cascade is partially activated in the presence of a consistent phenotype shift toward enhanced susceptibility to apoptosis. Although the system is still under a fragile control, the partial initiation of the apoptotic program may be of functional relevance also for the surviving cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823087     DOI: 10.1016/s0735-1097(01)01769-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

1.  Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  J Mol Histol       Date:  2015-06-04       Impact factor: 2.611

2.  Exercise training improves systolic function in hypertensive myocardium.

Authors:  Joseph R Libonati; Abdelkarim Sabri; Canhua Xiao; Scott M Macdonnell; Brian F Renna
Journal:  J Appl Physiol (1985)       Date:  2011-09-15

3.  X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector.

Authors:  Valentino Piacentino; Carmelo A Milano; Michael Bolanos; Jacob Schroder; Emily Messina; Adam S Cockrell; Edward Jones; Ava Krol; Nenad Bursac; Lan Mao; Gayathri R Devi; R Jude Samulski; Dawn E Bowles
Journal:  Hum Gene Ther       Date:  2012-03-13       Impact factor: 5.695

4.  Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction.

Authors:  D Santini; A Abbate; S Scarpa; F Vasaturo; G G Biondi-Zoccai; R Bussani; F De Giorgio; F Bassan; D Camilot; M P Di Marino; F Feroce; F Baldi; F Silvestri; F Crea; A Baldi
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

5.  Overexpression of IAP-2 attenuates apoptosis and protects against myocardial ischemia/reperfusion injury in transgenic mice.

Authors:  Chu Chang Chua; Jinping Gao; Ye-Shih Ho; Ye Xiong; Xingshun Xu; Zhongyi Chen; Ronald C Hamdy; Balvin H L Chua
Journal:  Biochim Biophys Acta       Date:  2007-01-25

6.  Concurrent upregulation of endogenous proapoptotic and antiapoptotic factors in failing human hearts.

Authors:  Nezam Haider; Eloisa Arbustini; Sudhir Gupta; Han Liu; Navneet Narula; Roger Hajjar; Narain Moorjani; Stephen Westaby; Marc J Semigran; G William Dec; Y Chandrashekhar; Jagat Narula
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

7.  Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway.

Authors:  Jie Ren; Wei Liu; Guang-Cai Li; Meng Jin; Zhen-Xi You; Hui-Guo Liu; Yi Hu
Journal:  Curr Med Sci       Date:  2018-06-22

Review 8.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

Review 9.  Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart.

Authors:  Yan Burelle; Maya Khairallah; Alexis Ascah; Bruce G Allen; Christian F Deschepper; Basil J Petrof; Christine Des Rosiers
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

10.  Right ventricular dilatation after left ventricular acute myocardial infarction is predictive of extremely high peri-infarctual apoptosis at postmortem examination in humans.

Authors:  R Bussani; A Abbate; G G L Biondi-Zoccai; A Dobrina; A M Leone; D Camilot; M P Di Marino; F Baldi; F Silvestri; L M Biasucci; A Baldi
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.